SAMRAT PHARMACHEM
|
The Current P/E Ratio of SAMRAT PHARMACHEM is -37.89.
| Share Price | ₹204.9 | Feb 26,2026 |
| Market Cap | ₹63.5 Cr | |
| Earnings-TTM | ₹-1.7 Cr | TTM-Standalone Results |
| Price/Earnings | -37.89x | Calculated as Market Cap/Earnings |
|---|---|---|
| Explore Stock Analytics | ||
Definition & Calculation of PE (Price/Earnings) ratio of SAMRAT PHARMACHEM
P/E =
Market Capitalization
/ Net Income
or, using per-share numbers:
P/E = Stock Price /
Earnings Per Share (EPS)
Current Market Cap [ ₹63.5 Cr] as on Feb 26,2026
(/) Earnings [ ₹-1.7 Cr] based on TTM-Standalone Results
(=) P/E Ratio [ -37.89x ]
Thus, for SAMRAT PHARMACHEM , the investors are currently willing to pay -37.89 times earnings to own 1 share of the company.
PE Multiples are the most widely used valuation multiple in practice.
Since P/E ratio uses Net Income in the calculation, P/E multiples are not always reliable for valuing companies with negative earnings.
In such cases, you may consider using Price to Book ratio or Price to Sales ratio of SAMRAT PHARMACHEM !
P/E ratios, also, would not adjust for differences in the capital structure between companies.
The chart below summarizes the trend in P/E Ratio of SAMRAT PHARMACHEM over the last five years.
Historical PE (Price/Earnings) ratio chart of SAMRAT PHARMACHEM
PE Ratio Performance Analysis for SAMRAT PHARMACHEM
- SAMRAT PHARMACHEM 's p/e ratio for fiscal years ending Mar2025 to Mar2021 averaged 16.94x.
- SAMRAT PHARMACHEM 's operated at median p/e ratio of 8.72x from fiscal years ending March 2018 to 2022.
- Looking back at the last 5 fiscal years, SAMRAT PHARMACHEM 's p/e ratio peaked in Mar2024 at 47.64x.
- SAMRAT PHARMACHEM 's p/e ratio hit its five-year low in Mar2023 of 6.89x.
How does SAMRAT PHARMACHEM 's P/E Ratio benchmark against top 10 peers in Pharmaceuticals & Drugs Industry?
| Peer Comparison (Pharmaceuticals & Drugs Industry) | Earnings-TTM (Cr) | PE Ratio | Market Cap |
|---|---|---|---|
| SAMRAT PHARMACHEM | -1.68 | -37.89 | 63.5 |
| SUN PHARMACEUTICAL INDUSTRIES LTD | 11,001.40 | 38.92 | 428,185.0 |
| DIVIS LABORATORIES LTD | 2,479.00 | 69.29 | 171,766.0 |
| CIPLA LTD | 4,544.70 | 24.13 | 109,680.0 |
| TORRENT PHARMACEUTICALS LTD | 2,272.00 | 65.55 | 148,923.0 |
| DR REDDYS LABORATORIES LTD | 5,508.70 | 19.98 | 110,081.0 |
| MANKIND PHARMA LTD | 1,796.65 | 52.39 | 94,121.6 |
| ZYDUS LIFESCIENCES LTD | 4,933.90 | 19.13 | 94,399.8 |
| LUPIN LTD | 4,669.18 | 22.74 | 106,180.0 |
| AUROBINDO PHARMA LTD | 3,513.20 | 20.20 | 70,974.0 |
| ABBOTT INDIA LTD | 1,524.13 | 36.72 | 55,961.5 |
Pharmaceuticals & Drugs Industry Benchmark (Top 10) PE Analysis vs SAMRAT PHARMACHEM 's P/E Ratio
| Top 10 Industry Peers | PE Ratio |
|---|---|
| Min industry PE | -37.89x |
| Max industry PE | 69.29x |
| Median industry PE | 24.13x |
| Average industry PE | 30.11x |
You may also like the below Video Courses